Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON) has appointed Nadim Ahmed to its Board of Directors. Ahmed, currently President and CEO of Cullinan Therapeutics, brings over 25 years of leadership experience in drug development and commercialization.

The appointment comes at a strategic time as Disc Medicine prepares for potential NDA filing and launch of bitopertin for EPP (erythropoietic protoporphyria). Ahmed's previous roles include President of Hematology at Bristol Myers Squibb and President of Global Hematology & Oncology at Celgene Corporation, where he oversaw multiple successful product launches.

Positive

• Strategic timing of appointment ahead of potential NDA filing and commercial launch
• New director brings 25+ years of relevant experience in drug development and commercialization
• Addition of executive with successful track record in product launches and hematology expertise

Negative

• None.

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics.

“I am excited to welcome Nadim to Disc’s Board of Directors at such a pivotal moment for the company,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “His track record of successful drug launches and deep expertise in hematological diseases will be invaluable as we advance bitopertin towards commercialization in EPP and continue development of the rest of our hematology pipeline.”

“With multiple meaningful catalysts expected in the coming months, including a potential NDA filing and launch for bitopertin in EPP, I am thrilled to be joining the Board of Disc at this exciting time,” Mr. Ahmed commented. “I look forward to partnering with the team as they work to transition Disc to a commercial-stage company and deliver on the full potential of its rich development pipeline.”

Mr. Ahmed joins the Disc Medicine Board with more than twenty-five years of leadership experience across a range of development and commercialization roles. He is currently the President and Chief Executive Officer at Cullinan Therapeutics, a biopharmaceutical company developing a pipeline of clinical-stage programs focused on oncology and autoimmune diseases. Prior to Cullinan Therapeutics, Mr. Ahmed worked at Bristol Myers Squibb, where he served as President, Hematology and at Celgene Corporation where he served as President, Global Hematology & Oncology. At Bristol Myers Squibb and Celgene, Mr. Ahmed oversaw multiple product launches and served as a member of both companies’ Leadership Teams. He holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements        

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectations with respect to its clinical development plans, related regulatory interactions, and the commercialization of bitopertin in EPP. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

FAQ

Who is the new Board member appointed to Disc Medicine (NASDAQ:IRON)?

Nadim Ahmed, current President and CEO of Cullinan Therapeutics, has been appointed to Disc Medicine's Board of Directors.

What is Nadim Ahmed's experience in the pharmaceutical industry?

Ahmed has over 25 years of leadership experience in drug development and commercialization, including roles as President of Hematology at Bristol Myers Squibb and President of Global Hematology & Oncology at Celgene Corporation.

What upcoming milestones does Disc Medicine (IRON) expect?

Disc Medicine expects multiple meaningful catalysts in the coming months, including a potential NDA filing and launch for bitopertin in EPP (erythropoietic protoporphyria).

What is Disc Medicine's (IRON) main business focus?

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious hematologic diseases.